Key Insights

Highlights

Treatment Research

1 treatments under study, led by Cytomegalovirus Immune Globulin Intravenous Human Monthly For Three Months

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 4 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT06958796Phase 4Recruiting

Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)

Showing all 1 trials

Research Network

Common Treatments

  • Cytomegalovirus Immune Globulin Intravenous Human Monthly For Three Months1

Active Sponsors

  • Kamada, Ltd.1
  • University of Texas Southwestern Medical Center1
  • Camille N. Kotton, MD1

Top Investigators

Related Conditions

  • Organ Transplant1
  • Cytomegalovirus1
  • Kidney Transplant Complications1
  • Liver Transplant Complications1

Activity Timeline